| Project/Area Number |
26462075
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nippon Medical School |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
松田 陽子 地方独立行政法人東京都健康長寿医療センター(東京都健康長寿医療センター研究所), 東京都健康長寿医療センター研究所, 研究員 (20363187)
内田 英二 日本医科大学, 大学院医学研究科, 大学院教授 (70176684)
石渡 俊行 地方独立行政法人東京都健康長寿医療センター(東京都健康長寿医療センター研究所), 東京都健康長寿医療センター研究所, 研究部長 (90203041)
|
|---|
| Research Collaborator |
Korc Murray Indiana University School of Medicine IU, Department of Medicine, Professor
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 膵癌 / STAT5 / 接着 / 浸潤 / ゲムシタビン抵抗性 / STAT5ｂ / STAT5b / ゲムシタビン / 抗癌剤感受性 / アポトーシス / Bcl-xL / 浸潤能 / 接着能 |
|---|
| Outline of Final Research Achievements |
In our study, expressions of signal transducers and activators of transcription 5a/5b (STAT5a/5b) mRNA and protein were detected in eight kinds of pancreatic cancer cells. STAT5a/5b in pancreatic cancer cells is constitutively activated. STAT5b shRNA clones in PANC-1 cells exhibited reduced chemoresistance against gemcitabine compared to sham. STAT5b shRNA clones in PANC-1 cells were more sensitive to the proapoptotic actions of gemcitabine, as evidenced by PARP and cleaved caspase 3 activation. Gemcitabine also significantly reduced Bcl-xL levels in the STAT5b shRNA-expressing cells. STAT5a/5b shRNA clones in PANC-1 exhibited reduced adhesion, and invasion These findings suggest that STAT5b confers gemcitabine chemoresistance and STAT5a/5b promotes cell adherence and invasiveness in pancreatic cancer cells. Targeting STAT5a/5b may lead to novel therapeutic strategies for pancreatic ductal adenocarcinoma.
|
